PharmaTalkRadio

About the Episode:

For those of us who work in clinical trials, we know all too well that the majority of sites don't hit recruitment targets, resulting in costly delays and burnout from sites and patients. 

Tegan Mead and Julie Mansson, both at Javara, describe how they are applying data and technology to identify the right fit and make sure that sites are set up for success, advising sponsors on making trials less burdensome for patients, and keeping physicians in the loop on trials for their patients, to make clinical trials more successful in more places, for the benefit of patients. 

 

About the Speakers: 

Tegan Mead, Executive Director of Operational Excellence, Javara

Tegan Mead began her career in clinical research in 2014, working as a Clinical Operations Manager at PMG Research. She has served in various roles across the site enterprise, including operational leadership, feasibility management and operational excellence, with most of her career centered on clinical operations execution, development, and growth. 

Julie Mansson, Associate Director, Project Strategy, Javara

Julie Mansson has over 24 years of clinical research experience primarily focused on trial implementation, study startup, and site operational development. For the last two and a half years she has served in several roles on Javara’s Project Strategy team, supporting cross-functional teams on trial feasibility and project optimization. 

 

For more information about clinical research as a care option, click here.

Innovating Patient Recruitment: A Conversation with BBK Worldwide Founders Joan F. Bachenheimer and Bonnie A. Brescia

 

The Conference Forum moderates a webcast featuring Joan F. Bachenheimer and Bonnie A. Brescia, the founders of BBK Worldwide, who walk us through the evolution of patient recruitment and engagement, the connection to the women’s and consumer healthcare movement, the need for changes in communication and the rise of the patient voice.

They also address the impact of scientific advances on patient recruitment and the importance of preparing to meet the evolving changes. The timing of the webcast coincides with the company’s 40-year anniversary.

 

Guests: 

Joan F. Bachenheimer, Founder, Chief Executive Officer, BBK Worldwide

Bonnie A. Brescia, Founder, Chief Development Officer, BBK Worldwide

 

Moderated by:

Valerie Bowling, Executive Director, Conference Forum

 

For more information on BBK Worldwide, visit www.bbkworldwide.com

For more information on the Conference Forum, visit www.theconferenceforum.org

Directors, Valerie Bowling and Kate Woda, discuss what to expect at the upcoming 10th annual Mobile Tech in Clinical Trials conference taking place on September 19, 2023 in Boston, MA.

Director, Valerie Bowling, reviews what to expect at the upcoming Clinical Research as a Care Option (CRAACO) conference taking place on May 22-23 at the Sheraton Imperial Hotel in Raleigh-Durham, NC.

In this podcast, you will hear a panel discussion moderated by Paul Jansen from the 2022 PODD Conference regarding the biggest challenges as well as future solutions to vaccine administration and distribution.

Panelists include:

Jeffrey T Blue, MerckDerek O’Hagan, PhD, GSK

To learn more about the PODD Conference, please visit PODDConference.com.

In this podcast, you will hear a panel discussion moderated by Mark DeStefano, Teva, from the 2022 PODD Conference regarding balancing the level of connected activity with user needs, determining how broadly or specifically to use connectivity and slowly implementing connectivity to provide good user acceptance.

Panelists include:

Kevin Deane, Phillips-Medisize, a Molex CompanyDavid Harrison, UCBLilly StairsBrad Womble, JabilAndrei Yosef, Eitan Medical

To learn more about the PODD Conference, please visit PODDConference.com.

Why is enhancing the interferon pathway an attractive approach for treating cancer?What are the novel therapeutic approaches being investigated to harness the innate immune system to enhance the interferon pathway to treat cancer?What are the translational approaches being applied to better study therapeutics that activate the interferon pathway against hematologic and solid tumors and identify the patients who may respond better to these therapeutics?

Christine Ward, PhD, Head, oncology Precision and Translational Medicine, Takeda Pharmaceuticals

Learn more about the IO360° Summit at www.io360summit.com

In this talk, first recorded at the 2022 IO360° Summit, Dr Rachel Haurwitz, CEO, Caribou Biosciences, addresses the big picture view of where the cell therapy field is going and how innovative CRISPR-based editing will help with the treatment of hematologic and solid tumors. Key topics include:

Approach that requires highly specific and efficient multiplex genome editingWhat are some of the potential stumbling blocks?What are the tools for solving those challenges?Tackling solid tumors as the next frontier for cell therapies

Rachel Haurwitz, PhD, President & CEO, Caribou Biosciences

Learn more about the IO360° Summit at www.io360summit.com

Moderated by:

Axel Hoos, MD, PhD, CEO, Scorpion Therapeutics

Panelists:

Jonathan Fassberg, Vice Chairman of Healthcare Investment Banking, OppenheimerIrina Margine, PhD, Principal, Biotech Private Equity, Wellington ManagementAsthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst, Truist SecuritiesGraig Suvannavejh, PhD, Managing Director, Equity Research Biopharmaceuticals & Biotechnology, Mizuho Securities USA

Learn more about the IO360° Summit at www.io360summit.com

This panel, first recorded at the 2022 IO360° Summit addressed:

What are the risks and implications of investing in cell/gene therapy companies who have no clinical data from programs available?Venture company perspectives on what they are investing in and why? • What science needs to be seen in order to invest in either a startup or IPO?What are investors/pharma partners looking for and how does that inform what people should be doing?How do we think about partnerships between organizations?

Moderated by:

Michael Polansky, CEO, Parker Group

Panelists:

Mark Bonyhadi, PhD, Senior Advisor, Qiming Venture PartnersElaine Cheung, SVP, Corporate Strategy & Business Development, Lyell ImmunopharmaArjun Goyal, MD, MPhil, MBA, Co-founder and Managing Director, Vida Ventures

Learn more about the IO360° Summit at www.io360summit.com